Molnupiravir does not induce resistance mutations in SARS-CoV-2 genome researchsquare LSTMnews SARSCoV2 COVID19 Molnupiravir
By Dr. Sanchari Sinha Dutta, Ph.D.Jul 19 2022Reviewed by Aimee Molineux A new study currently available on the Research Square* preprint server has pointed out that molnupiravir treatment increases the ratio of transition to transversion mutations in coronavirus disease 2019 patients and that the treatment does not appear to induce resistance mutations in the severe acute respiratory syndrome coronavirus 2 genome.
In the AGILE Candidate Specific Trial -2, the scientists evaluated the risk of mutation accumulation in COVID-19 patients treated with molnupiravir. Related StoriesSerial nasopharyngeal samples were collected from the patients over 29 days. The samples were subjected to genome quality control testing, which led to identifying viral sequences from 59 molnupiravir-treated patients and 65 placebo-treated patients.
To address whether molnupiravir treatment is associated with preferential enrichment of mutations in the viral RNA, the scientists performed in silico translation of the viral sequences at both the dominant and minor variant genome levels and analyzed molnupiravir-induced mutations. An induction in viral sequence diversity was observed during the treatment in both study groups, with molnupiravir-treated group showing higher diversity at day 5. The diversity was observed throughout the viral genome, with a slight bias towards the 3’ end.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study results encourage SARS-CoV-2–infected mothers breastfeed to protect infants from COVIDStudy results encourage SARS-CoV-2–infected mothers breastfeed to protect infants from COVID Antibodies ChildHealth Coronavirus Disease COVID SARSCoV2 breastmilk cordblood newborn pregnant glycoprotein
Read more »
What is the impact of SARS-CoV-2 variant booster vaccinations?What is the impact of SARS-CoV-2 variant booster vaccinations? medrxivpreprint UofR SARSCoV2 COVID19 Booster Vaccination
Read more »
The known and proposed interactions of SARS-CoV and SARS-CoV-2 with DNA damage response pathwaysThe known and proposed interactions of SARS-CoV and SARS-CoV-2 with DNA damage response pathways _ZewailCity_ RIMUHC1 SARSCoV2 SARSCoV DNA DNAdamage virus covid coronavirus
Read more »
Analyzing whether SARS-CoV-2 nucleocapsid and spike proteins stimulate dendritic or γδ T cellsAnalyzing whether SARS-CoV-2 nucleocapsid and spike proteins stimulate dendritic or γδ T cells tcddublin SARSCoV2 COVID19 Spike DendriticCells
Read more »
Scientists evaluate immunostimulatory glycolipid against SARS-CoV-2 infectionA new study showed that 7DW8-5, an immunostimulatory glycolipid impeded three respiratory viral infections, including SARS-CoV-2, in vivo.
Read more »
SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodiesSARS-CoV-2 host-shutoff inhibits innate NK surveillance by suppressing activating ligands, however ADCC provides a potent NK stimulus that is mediated by antibodies targeting Nucleocapsid, ORF3a, and Membrane, with those targeting Spike being significantly weaker.
Read more »